Developer docs
API playgroundTry for free, no card

Search company profiles

Sciety

Full company profile

uuid0002yjx

Namestring
Sciety
Websiteurl
sciety.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Sciety is a Stockholm-based, privately held Nordic investment firm founded in 2014 that focuses exclusively on healthcare and life sciences. The firm operates with 11-50 employees under a founder-led management team (CEO Andreas Lindblom, CFO/COO Malin Lindblom, corporate finance directors Dawid Myslinski and Håkan Lampa) and a small functional staff covering marketing, IT, and project management. Its investment activity centers on leading or participating in financing rounds for Swedish and Nordic biotech, healthtech, and medical technology companies across verticals including precision diagnostics, personalized cancer immunotherapy, digital primary care, pharmaceutical manufacturing tools, and drone-based emergency healthcare.

Sciety's underlying technology is essentially its investment management platform and sector knowledge rather than a licensable product; the proprietary advantage lies in deal sourcing, diligence, and follow-on support within Nordic life sciences. The firm has reached its tenth portfolio exit via the Foundation Medicine (Roche subsidiary) agreement to acquire Saga Diagnostics for up to USD 595 million, marking a milestone in its precision diagnostics thesis. Visible recent deployments include a SEK 87 million round into Neogap Therapeutics, a SEK 40 million round into Hälsa Hemma, a SEK 36 million round into Everdrone, and a EUR 3.9 million investment in PeptiSystems (later co-invested by Rubicon Healthcare Partners).

The business model is investment-driven: Sciety earns revenue primarily through equity returns on portfolio companies, with deal-flow originating from direct Nordic industry networks and co-investor relationships. Go-to-market is enterprise-style direct investment into portfolio companies rather than traditional B2B sales, and pricing/contract structures are not publicly disclosed. There are no disclosed enterprise customers, marketing channels, or product integrations at the firm level, and the company's headquarters remains its principal operating base in Stockholm.

Short descriptiontext

Sciety is a Stockholm-based Nordic investment firm founded in 2014 that leads financing rounds in Swedish and Nordic healthcare and life sciences companies across biotech, healthtech, and medical technology, and has reached ten portfolio exits including Saga Diagnostics to Roche.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
venture capital services, healthcare investment, life sciences funding, private equity, growth capital
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Other Financial Investment Activities5239
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Private Equity (Healthcare Focus)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeTransaction Fee
Description

Sciety generates returns through equity investments in healthcare and life sciences companies, with exits such as the Saga Diagnostics acquisition by Foundation Medicine (Roche subsidiary) for up to USD 595 million, representing their tenth exit.

news.cision.com
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sciety is a Nordic investment company that deploys venture and growth capital into healthcare and life sciences companies, primarily across the Nordics. The firm invests in early- and growth-stage businesses in areas such as medical devices, digital health, biotechnology, and related healthcare innovation, generating returns through equity ownership, investment income, and transaction-based exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 10th exit achieved through Saga Diagnostics acquisition by Foundation Medicine/Roche for up to USD 595 million
+1 more record
Product overview1 text field

Sciety is a Nordic investment company that focuses on investing in healthcare and life science companies. The company does not offer a technology product or service in the traditional SaaS sense; rather, it operates as an investment firm that builds and manages a portfolio of healthtech, biotech, and medical technology companies.

Product and service1 record
1Healthcare and Life Sciences Venture & Growth Capital
CategoryVenture Capital / Private Equity
Description

Equity capital provided to Nordic healthcare and life sciences companies across early- and growth-stage rounds; intended for founders, management teams, and boards of privately held healthcare companies (including medical devices, digital health, and biotechnology) seeking specialized sector investment.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Industrifonden (now renamed Saminvest) is a Nordic venture and growth capital investor with significant healthcare and life sciences exposure, backing Swedish and Scandinavian companies. Comparable to Sciety as a Swedish-rooted growth investor participating in similar financing rounds and sectors.

2EQT Life Sciences
TypeBroad incumbent
Description

EQT Life Sciences (formerly LSP) is the dedicated life sciences arm of EQT, a major European private equity firm, investing in biotech, medtech, and diagnostics across Europe. Comparable to Sciety as a larger, well-established healthcare investor operating in the same geographies and asset classes but at materially greater scale.

TypeDirect peer
Description

Kurma Partners is a European healthcare-focused venture capital firm investing in biotech and digital health across Europe. Directly comparable to Sciety as a healthcare-dedicated European VC targeting therapeutics, diagnostics, and healthtech opportunities.

TypeDirect peer
Description

Medicxi is a European life sciences-focused investment firm backing asset-centric biotech and specialty pharma companies. Comparable to Sciety as a European healthcare investor focused on therapeutics development, though operating across broader European geographies.

5Roslin Capital
TypeDirect peer
Description

Roslin Capital is a Scottish/Nordic-connected life sciences investor backing early-stage biotech and medtech companies. Comparable to Sciety as a Northern European healthcare specialist investor targeting similar company stages.

TypeDirect peer
Description

Atlas Venture is a biotech-focused early-stage venture capital firm creating and building breakthrough therapeutics companies. Comparable to Sciety as a sector-specialized biotech investor with a thesis-driven company-creation approach, though primarily US-focused rather than Nordic.

TypeDirect peer
Description

HealthCap is a Nordic venture capital firm focused exclusively on healthcare and life sciences, investing in therapeutics, medical devices, and diagnostics. Directly comparable to Sciety as a sector-specialized Nordic healthcare investor with multiple funds and a long exit track record.

TypeDirect peer
Description

Novo Holdings' Novo Seeds program is a Nordic life sciences venture investor backing early-stage biotech, medtech, and diagnostics companies across Scandinavia. Directly comparable as a Nordic healthcare specialist investor with deep sector expertise and an active portfolio similar to Sciety's.

TypeDirect peer
Description

Forbion is a European venture capital firm focused on life sciences and biotech, investing across therapeutics and diagnostics. Directly comparable to Sciety as a healthcare-dedicated VC with a pan-European footprint, though at a larger scale than Sciety.

TypeDirect peer
Description

Sunstone Capital is a Danish/Nordic venture capital firm with a dedicated life sciences practice backing biotech and medtech companies in the region. Directly comparable to Sciety as a Nordic-focused healthcare investor targeting similar company stages and verticals.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment43 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sciety

Venture Capital / Private Equity (Healthcare Focus)sciety.com

Sciety is a Stockholm-based Nordic investment firm founded in 2014 that leads financing rounds in Swedish and Nordic healthcare and life sciences companies across biotech, healthtech, and medical technology, and has reached ten portfolio exits including Saga Diagnostics to Roche.

What Sciety does

Sciety is a Stockholm-based, privately held Nordic investment firm founded in 2014 that focuses exclusively on healthcare and life sciences. The firm operates with 11-50 employees under a founder-led management team (CEO Andreas Lindblom, CFO/COO Malin Lindblom, corporate finance directors Dawid Myslinski and Håkan Lampa) and a small functional staff covering marketing, IT, and project management. Its investment activity centers on leading or participating in financing rounds for Swedish and Nordic biotech, healthtech, and medical technology companies across verticals including precision diagnostics, personalized cancer immunotherapy, digital primary care, pharmaceutical manufacturing tools, and drone-based emergency healthcare.

Sciety's underlying technology is essentially its investment management platform and sector knowledge rather than a licensable product; the proprietary advantage lies in deal sourcing, diligence, and follow-on support within Nordic life sciences. The firm has reached its tenth portfolio exit via the Foundation Medicine (Roche subsidiary) agreement to acquire Saga Diagnostics for up to USD 595 million, marking a milestone in its precision diagnostics thesis. Visible recent deployments include a SEK 87 million round into Neogap Therapeutics, a SEK 40 million round into Hälsa Hemma, a SEK 36 million round into Everdrone, and a EUR 3.9 million investment in PeptiSystems (later co-invested by Rubicon Healthcare Partners).

The business model is investment-driven: Sciety earns revenue primarily through equity returns on portfolio companies, with deal-flow originating from direct Nordic industry networks and co-investor relationships. Go-to-market is enterprise-style direct investment into portfolio companies rather than traditional B2B sales, and pricing/contract structures are not publicly disclosed. There are no disclosed enterprise customers, marketing channels, or product integrations at the firm level, and the company's headquarters remains its principal operating base in Stockholm.

Sciety firmographics

Firmographics
Name
Sciety
Website
https://sciety.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Sciety is a Stockholm-based Nordic investment firm founded in 2014 that leads financing rounds in Swedish and Nordic healthcare and life sciences companies across biotech, healthtech, and medical technology, and has reached ten portfolio exits including Saga Diagnostics to Roche.
Ownership category
akta.pro rank

Sciety industry classification

Industry
Product category
Venture Capital / Private Equity (Healthcare Focus)
NAICS
Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital services
  • Healthcare investment
  • Life sciences funding
  • Private equity
  • Growth capital

Where Sciety is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Markets served

Sciety business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Investment Returns: Sciety generates returns through equity investments in healthcare and life sciences companies, with exits such as the Saga Diagnostics acquisition by Foundation Medicine (Roche subsidiary) for up to USD 595 million, representing their tenth exit.

Go-to-market motion1 record

Sciety product offering

Product offering

Core offering

Sciety is a Nordic investment company that deploys venture and growth capital into healthcare and life sciences companies, primarily across the Nordics. The firm invests in early- and growth-stage businesses in areas such as medical devices, digital health, biotechnology, and related healthcare innovation, generating returns through equity ownership, investment income, and transaction-based exits.

Product overview

Sciety is a Nordic investment company that focuses on investing in healthcare and life science companies. The company does not offer a technology product or service in the traditional SaaS sense; rather, it operates as an investment firm that builds and manages a portfolio of healthtech, biotech, and medical technology companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare and Life Sciences Venture & Growth Capital Equity capital provided to Nordic healthcare and life sciences companies across early- and growth-stage rounds; intended for founders, management teams, and boards of privately held healthcare companies (including medical devices, digital health, and biotechnology) seeking specialized sector investment.

Quantifiable outcome

  • 10th exit achieved through Saga Diagnostics acquisition by Foundation Medicine/Roche for up to USD 595 million
  • +1 more outcomes

Companies that use Sciety

Customer profile

Segments5 records

Ideal customer profiles1 record

Sciety technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sciety partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Sciety competitors and assessment

Company assessment

Direct peers

  • Industrifonden: Industrifonden (now renamed Saminvest) is a Nordic venture and growth capital investor with significant healthcare and life sciences exposure, backing Swedish and Scandinavian companies. Comparable to Sciety as a Swedish-rooted growth investor participating in similar financing rounds and sectors.
  • Kurma Partners: Kurma Partners is a European healthcare-focused venture capital firm investing in biotech and digital health across Europe. Directly comparable to Sciety as a healthcare-dedicated European VC targeting therapeutics, diagnostics, and healthtech opportunities.
  • Medicxi: Medicxi is a European life sciences-focused investment firm backing asset-centric biotech and specialty pharma companies. Comparable to Sciety as a European healthcare investor focused on therapeutics development, though operating across broader European geographies.
  • Roslin Capital: Roslin Capital is a Scottish/Nordic-connected life sciences investor backing early-stage biotech and medtech companies. Comparable to Sciety as a Northern European healthcare specialist investor targeting similar company stages.
  • Atlas Venture: Atlas Venture is a biotech-focused early-stage venture capital firm creating and building breakthrough therapeutics companies. Comparable to Sciety as a sector-specialized biotech investor with a thesis-driven company-creation approach, though primarily US-focused rather than Nordic.
  • HealthCap: HealthCap is a Nordic venture capital firm focused exclusively on healthcare and life sciences, investing in therapeutics, medical devices, and diagnostics. Directly comparable to Sciety as a sector-specialized Nordic healthcare investor with multiple funds and a long exit track record.
  • Novo Holdings (Novo Seeds): Novo Holdings' Novo Seeds program is a Nordic life sciences venture investor backing early-stage biotech, medtech, and diagnostics companies across Scandinavia. Directly comparable as a Nordic healthcare specialist investor with deep sector expertise and an active portfolio similar to Sciety's.
  • Forbion: Forbion is a European venture capital firm focused on life sciences and biotech, investing across therapeutics and diagnostics. Directly comparable to Sciety as a healthcare-dedicated VC with a pan-European footprint, though at a larger scale than Sciety.
  • Sunstone Capital: Sunstone Capital is a Danish/Nordic venture capital firm with a dedicated life sciences practice backing biotech and medtech companies in the region. Directly comparable to Sciety as a Nordic-focused healthcare investor targeting similar company stages and verticals.

Broad incumbents

  • EQT Life Sciences: EQT Life Sciences (formerly LSP) is the dedicated life sciences arm of EQT, a major European private equity firm, investing in biotech, medtech, and diagnostics across Europe. Comparable to Sciety as a larger, well-established healthcare investor operating in the same geographies and asset classes but at materially greater scale.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Sciety financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sciety leadership team

Management profile

Number of profiles

Profiles7 records

Sciety funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sciety M&A and investment

M&A and investment

M&A

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sciety

What does Sciety do?

Sciety is a Nordic investment company that deploys venture and growth capital into healthcare and life sciences companies, primarily across the Nordics. The firm invests in early- and growth-stage businesses in areas such as medical devices, digital health, biotechnology, and related healthcare innovation, generating returns through equity ownership, investment income, and transaction-based exits.

Is Sciety a public or private company?

Sciety is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sciety founded?

Sciety was founded in 2014. It employs 11 to 50 people.

Where is Sciety based?

Sciety is headquartered in Stockholm, Sweden, in the Europe region.

How does Sciety make money?

One revenue line is on record: investment Returns.

Who are Sciety's main competitors?

Direct peers on record are Industrifonden, Kurma Partners, Medicxi, Roslin Capital, Atlas Venture, HealthCap, Novo Holdings (Novo Seeds), Forbion and Sunstone Capital. EQT Life Sciences is listed as a broad incumbent.

Does Sciety have an API?

No public API is recorded for Sciety.

What industry is Sciety in?

Sciety's product category is Venture Capital / Private Equity (Healthcare Focus). Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comSciety welcomes Recipharm co-founder Thomas Eldered as Senior AdvisorSciety appointed Thomas Eldered, co-founder of Recipharm and founder of Flerie, as Senior Advisor. He brings over 35 years of pharmaceutical industry experience, including leading Recipharm to SEK 11 billion annual revenue and 9,000 employees. Sciety CEO Anna Sundin said his investment and life science expertise will be valuable.news.cision.comSciety appoints Anna Sundin as new Managing DirectorSciety's board appointed Anna Sundin as Managing Director, succeeding founder Andreas Lindblom, who will remain Managing Partner. Sundin brings 25 years of financial sector experience from BearingPoint, where she led M&A in the Nordics. She took office on 16 September.news.cision.comSciety portfolio company Saga Diagnostics acquired by Foundation Medicine, a subsidiary of RocheSaga Diagnostics, a biotechnology company developing cancer diagnostic tests, has agreed to be acquired by Foundation Medicine, an independent subsidiary of Roche, for up to USD 595 million including milestone payments. The deal, expected to close in Q3 2026 pending regulatory approvals, will integrate Saga's Pathlight™ blood-based MRD test platform into Foundation Medicine's operations. The acquisition marks Sciety's tenth exit and represents a significant milestone in the growing precision diagnostics sector, particularly in liquid biopsy-based cancer detection.NeogapNeogap secures SEK 87 million to advance clinical development of its personalised immunotherapy – NEOGAPSwedish biotechnology company Neogap Therapeutics has raised SEK 87 million in a financing round led by Sciety to advance its ongoing first-in-human clinical trial of personalised cell therapy for advanced colorectal cancer. The funding will support the continuation of the trial, which has shown that the treatment is well tolerated, and enable preparations for the next stage of clinical development. Neogap has also received approval from the Swedish Medical Products Agency to treat all patients in the study at full dose.news.cision.comSciety leads SEK 87 million financing round in Neogap TherapeuticsSciety led a SEK 87 million financing round for Neogap Therapeutics, a Swedish biotech company developing personalized cancer immunotherapy, to support ongoing clinical trials and future commercialization. The company's therapy, pTTL, has shown positive safety results and is being tested in a colorectal cancer trial in Sweden. The funding aims to advance clinical development and scale manufacturing capabilities, driven by significant market potential.The Pharma LetterNeogap capital raise for clinical development of personalized immunotherapySwedish biotech Neogap Therapeutics has raised 87 million Swedish kronor ($9.8 million) in a financing round led by Nordic investment company Sciety. The funds will support clinical development of personalized cancer immunotherapy using the patient's own cells. This represents a significant capital injection for the company's pipeline advancement.ScietySciety leads SEK 87 million financing round in Neogap TherapeuticsSciety led a SEK 87 million financing round for Neogap Therapeutics, a Swedish clinical-stage biotech company developing personalised immunotherapy for cancer. The capital will fund the company's ongoing Phase I/II clinical trial evaluating pTTL therapy for colorectal cancer and support data collection for the next development stage. Neogap has achieved key milestones including treating first patients, presenting positive initial safety data, and receiving approval to administer full doses to all trial participants.news.cision.comSciety leads SEK 40 million financing round for Hälsa Hemma – building next-generation primary careSciety, a Swedish life science and health tech investment firm, led a SEK 40 million financing round for Hälsa Hemma, a Swedish healthtech company providing next-generation primary care through a digiphysical model combining digital and in-home care services. The investment will fund Hälsa Hemma's expansion into new regions, further development of its AI-driven platform, and operational capacity strengthening. Hälsa Hemma is EBITDA-positive with an annual revenue run rate of approximately SEK 60 million and operates in Stockholm, Gothenburg, and Malmö/Lund, covering over 5.5 million inhabitants.ScietySciety leads SEK 40 million financing round for Hälsa Hemma – building next-generation primary careSciety led a SEK 40 million financing round for Swedish healthtech company Hälsa Hemma, which provides next-generation primary care through a digiphysical model combining digital consultations with in-home visits. The company is EBITDA-positive with an annual revenue run rate of approximately SEK 60 million and operates in Stockholm, Gothenburg, and Malmö/Lund, covering over 5.5 million inhabitants. The capital will fund expansion to new regions, further development of the AI-driven platform, and strengthened operational capacity.